MAPK/ERK signaling promotes drug resistance by inducing epithelial–mesenchymal transition, while suppression of PI3K/AKT/mTOR pathway can reverse oxaliplatin resistance of CRC cells and increases irinotecan sensitivity. This evidence concerns the gene MTOR and colorectal carcinoma.